Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Rational for HER3-targeting in NRG1 fusion-positive NSCLC

Alison Schram • 21 Oct 2023
ESMO 2023
Lung Cancer Non-Small Cell Lung Cancer

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explains the rational for targeting HER3 in neuregulin 1 (NRG1) fusion-positive non-small cell lung cancer (NSCLC). This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alison Schram

0:46
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
Alison Schram • 21 Oct 2023
1:56
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023
1:31
Optimizing and overcoming resistance to current KRAS inhibitors
Alison Schram • 18 Apr 2023
1:04
AACR 2023 highlights in PI3Kα and FGFR inhibition
Alison Schram • 18 Apr 2023

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals